Assoc. Prof. Dr. Yuchen Liu , Shenzhen Institute of Translational Medicine , China.
Dr. Yuchen Liu 🧑🔬 is the Deputy Director at the Shenzhen Institute of Translational Medicine and an Associate Research Fellow at Shenzhen Second People’s Hospital 🏥. As a Principal Investigator 👨🏫 and doctoral supervisor 🎓, he leads pioneering research in gene therapy 🧫, synthetic biology 🔬, and translational medicine 💉. Recognized in Forbes Asia’s “30 Under 30” 🌟 and GEN’s “Top 10 Under 40” 🏅, he has authored 50+ SCI papers 📚, holds 14 patents ⚙️, and drives innovation through national R&D programs 🇨🇳. His work bridges academia and industry, advancing precision oncology and AI-driven drug discovery 🤖🧠.
Publication Profile
Education and Experience
-
🎓 Ph.D. in relevant biomedical sciences
-
🏥 Deputy Director, Shenzhen Institute of Translational Medicine
-
👨🏫 Principal Investigator, Shenzhen Second People’s Hospital
-
📘 Doctoral Supervisor in translational medicine
-
🧠 Led 6 major national/provincial research projects (NSFC, National Key R&D)
-
💼 Long-term collaborations with hospitals and biotech companies in Shenzhen
-
🧬 Active role in gene therapy, synthetic biology, and precision oncology
Summary Suitability
Dr. Yuchen Liu, Ph.D., is a leading biomedical scientist and Deputy Director at the Shenzhen Institute of Translational Medicine. Renowned for his groundbreaking work in gene therapy, synthetic biology, and precision oncology, Dr. Liu has consistently translated scientific discoveries into real-world healthcare innovations. With a research career marked by high-impact publications, national-level funding, and clinical collaboration, he has become a recognized force in China’s translational medicine landscape. His leadership, interdisciplinary approach, and scientific excellence strongly position him as a top contender for the Best Researcher Award.
Professional Development
Dr. Liu has cultivated a robust scientific career at the crossroads of research, innovation, and education 🎓🔬. As PI of numerous government-funded projects 🇨🇳, he has propelled forward the translational landscape of Shenzhen through impactful research and industrial collaborations 🤝. His expertise in synthetic biology 🧬 has enabled groundbreaking advances in gene circuits, RNA therapeutics, and programmable medicine 🧫⚙️. With 14 patents and 50+ SCI papers 📑, he exemplifies leadership in biomedical innovation. By mentoring students and leading interdisciplinary teams 👨👩👧👦, he contributes to academic growth while integrating AI 🤖 and synthetic systems in therapeutic development 🌐💊.
Research Focus
Dr. Liu’s research is rooted in translational medicine and focuses on gene therapy, synthetic biology, and precision oncology 🧬🧫. His innovations include multi-target gene regulation systems, AI-guided drug discovery 🤖💊, and RNA-based therapeutics 🧠💉. Liu’s projects bridge the lab-to-clinic gap, aiming for real-world impact in cancer treatment and personalized medicine 🎯. Through academic-industry partnerships and national-level leadership, he fosters high-throughput experimentation and clinical integration 🏥🔍. His multidisciplinary approach embraces genomics, bioinformatics, and smart therapeutics, transforming complex diseases into actionable solutions 🌐🔓.
Awards and Honors
-
🏅 Forbes Asia “30 Under 30” Honoree
-
🌟 GEN “Top 10 Under 40” Biotech Innovator
-
🧑🎓 Guangdong Distinguished Young Scholar
-
📜 Recognized PI of 6 national/provincial R&D projects
-
🧬 Editorial Board Member of top molecular biology journals
-
🎖️ Reviewer for prestigious journals like Nature Methods and JACS
-
⚙️ Holder of 14 authorized Chinese invention patents
Publication Top Notes
-
🧬 Exosome-transmitted LUCAT1 promotes stemness transformation and chemoresistance in bladder cancer by binding to IGF2BP2
Zhan, Yonghao; Zhou, Zhenzhen; Zhu, Zhaowei; Liu, Yuchen; Zhang, Xuepei
Journal: Journal of Experimental and Clinical Cancer Research (2025)
Type: Research Article • Open Access
-
🧠 DNA storage: The future direction for medical cold data storage
Shen, Peilin; Liu, Yuchen; Cai, Zhiming
Journal: [Journal name not listed] (2025)
Type: Review Article • Open Access
-
🧪 Engineering artificial non-coding RNAs for targeted protein degradation
Cao, Congcong; Li, Aolin; Xu, Chaojie; Yao, Lin; Liu, Yuchen
Journal: Nature Chemical Biology (2025)
Type: Research Article
-
🔐 Innovative logic “AND” gate gene circuits for bladder cancer treatment: preclinical study
Xu, Chaojie; Dong, Ying; Pei, Dongchen; Liu, Yuchen; Yao, Lin
Journal: International Journal of Surgery (2025)
Type: Research Article • Open Access
-
🧫 SAPCD2 as a New Biomarker and Potential Therapeutic Target in Pancreatic Cancer
Liu, Yuting; Li, Bo; Ke, Lingling; Liu, Yuchen; Qi, Jian
Journal: Journal of Inflammation Research (2025)
Type: Research Article • Open Access
-
🧬 YTH domain family protein 3 accelerates NSCLC immune evasion via CD8+ T cell suppression
Luo, Yisheng; Zeng, Chao; Ouyang, Zezhong; Liu, Yuchen; Wu, Hao
Journal: Cell Death Discovery (2024)
Type: Research Article • Open Access
Conclusion
Dr. Yuchen Liu exemplifies the essence of a modern researcher—innovative, collaborative, and impact-driven. His work has significantly advanced the frontiers of synthetic biology and cancer therapeutics while contributing to China’s growing global influence in biomedical research. With his unique combination of academic rigor, translational success, and visionary leadership, Dr. Liu is exceptionally qualified for the Best Researcher Award, and his recognition would be a celebration of both personal excellence and institutional innovation.